Conversely, a study with 508 MM patients showed a faster hematologic recovery and reduced hospitalization with CD34+ cell dose of ≥6.55 × 106 cells/kg with CD34+ cell selection, and ≥ 7.50 × 106 cells/kg without CD34+ cell selection. The gene discussed is CD34; the disease is Miyoshi myopathy.